Research programme: niacin receptor agonists - Arena Pharmaceuticals/Merck & Co

Drug Profile

Research programme: niacin receptor agonists - Arena Pharmaceuticals/Merck & Co

Latest Information Update: 24 Dec 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arena Pharmaceuticals
  • Developer Arena Pharmaceuticals; Merck & Co
  • Class Anthranilic acids; Small molecules
  • Mechanism of Action G protein-coupled receptor agonists; GPR109A receptor agonists; GPR109B receptor agonists; Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Atherosclerosis

Most Recent Events

  • 24 Dec 2009 Discontinued - Preclinical for Atherosclerosis in USA (PO)
  • 20 Aug 2009 Pharmacodynamics data from a Preclinical trial in Atherosclerosis presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)
  • 20 Feb 2009 Preclinical development is ongoing in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top